A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension
Objectives. To systematically evaluate the differences in effect and safety of LCZ696 and angiotensin receptor blockers (ARBs) in the treatment of hypertension. Methods. We searched PubMed, Cochrane, Web of Science, and Ovid, collected randomized controlled trials (RCTs) about the effect and safety...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Cardiology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2021/8867578 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552786960580608 |
|---|---|
| author | Li Zheng Binbin Xia Xuqian Zhang Yan Zhao |
| author_facet | Li Zheng Binbin Xia Xuqian Zhang Yan Zhao |
| author_sort | Li Zheng |
| collection | DOAJ |
| description | Objectives. To systematically evaluate the differences in effect and safety of LCZ696 and angiotensin receptor blockers (ARBs) in the treatment of hypertension. Methods. We searched PubMed, Cochrane, Web of Science, and Ovid, collected randomized controlled trials (RCTs) about the effect and safety of LCZ696 and ARBs in hypertensive patients, extracted relevant data and evaluated the quality of the included literature according to the RCT quality evaluation standard recommended by Cochrane Reviewer’s Handbook, using RevMan 5.3, and performed meta-analysis. Results. Eight RCTs studies were included, with a total of 4313 patients. Compared with ARBs, LCZ696 can better reduce systolic blood pressure (msSBP) (WMD −4.29 mmHg; 95% CI: −5.37 to −3.21; P < 0.001), diastolic blood pressure (msDBP) (WMD −1.87 mmHg; 95% CI:−2.38 to −1.36; P < 0.01), ambulatory systolic blood pressure (maSBP) (WMD −3.37 mmHg; 95% CI:−4.26 to −2.47; P < 0.01), and ambulatory diastolic blood pressure (maDBP) (WMD −1.47 mmHg; 95% CI: −1.97 to −0.97; P < 0.01). In terms of safety, LCZ696 is basically the same as ARBs, but LCZ696 is more likely to cause cough than ARBs (OR = 2.38; 95% CI: 1.27 to 4.47; P < 0.01). Conclusion. LCZ696 can significantly reduce the blood pressure level of patients with hypertension, but it is necessary to pay attention to whether the patient will experience coughing after taking the drug. |
| format | Article |
| id | doaj-art-870af91d6db34a3f9e509dfde980a1c2 |
| institution | Kabale University |
| issn | 2090-8016 2090-0597 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiology Research and Practice |
| spelling | doaj-art-870af91d6db34a3f9e509dfde980a1c22025-02-03T05:57:52ZengWileyCardiology Research and Practice2090-80162090-05972021-01-01202110.1155/2021/88675788867578A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of HypertensionLi Zheng0Binbin Xia1Xuqian Zhang2Yan Zhao3Department of Pharmacy, China Aerospace Science & Industry Corporation 731 Hospital, Beijing 100074, ChinaDepartment of Pharmacy, Luhe Hospital, Beijing 101149, ChinaDepartment of Gastroenterology and Hepatology, China Aerospace Science & Industry Corporation 731 Hospital, Beijing 100074, ChinaDepartment of Pharmacy, China Aerospace Science & Industry Corporation 731 Hospital, Beijing 100074, ChinaObjectives. To systematically evaluate the differences in effect and safety of LCZ696 and angiotensin receptor blockers (ARBs) in the treatment of hypertension. Methods. We searched PubMed, Cochrane, Web of Science, and Ovid, collected randomized controlled trials (RCTs) about the effect and safety of LCZ696 and ARBs in hypertensive patients, extracted relevant data and evaluated the quality of the included literature according to the RCT quality evaluation standard recommended by Cochrane Reviewer’s Handbook, using RevMan 5.3, and performed meta-analysis. Results. Eight RCTs studies were included, with a total of 4313 patients. Compared with ARBs, LCZ696 can better reduce systolic blood pressure (msSBP) (WMD −4.29 mmHg; 95% CI: −5.37 to −3.21; P < 0.001), diastolic blood pressure (msDBP) (WMD −1.87 mmHg; 95% CI:−2.38 to −1.36; P < 0.01), ambulatory systolic blood pressure (maSBP) (WMD −3.37 mmHg; 95% CI:−4.26 to −2.47; P < 0.01), and ambulatory diastolic blood pressure (maDBP) (WMD −1.47 mmHg; 95% CI: −1.97 to −0.97; P < 0.01). In terms of safety, LCZ696 is basically the same as ARBs, but LCZ696 is more likely to cause cough than ARBs (OR = 2.38; 95% CI: 1.27 to 4.47; P < 0.01). Conclusion. LCZ696 can significantly reduce the blood pressure level of patients with hypertension, but it is necessary to pay attention to whether the patient will experience coughing after taking the drug.http://dx.doi.org/10.1155/2021/8867578 |
| spellingShingle | Li Zheng Binbin Xia Xuqian Zhang Yan Zhao A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension Cardiology Research and Practice |
| title | A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension |
| title_full | A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension |
| title_fullStr | A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension |
| title_full_unstemmed | A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension |
| title_short | A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension |
| title_sort | meta analysis on the effect and safety of lcz696 in the treatment of hypertension |
| url | http://dx.doi.org/10.1155/2021/8867578 |
| work_keys_str_mv | AT lizheng ametaanalysisontheeffectandsafetyoflcz696inthetreatmentofhypertension AT binbinxia ametaanalysisontheeffectandsafetyoflcz696inthetreatmentofhypertension AT xuqianzhang ametaanalysisontheeffectandsafetyoflcz696inthetreatmentofhypertension AT yanzhao ametaanalysisontheeffectandsafetyoflcz696inthetreatmentofhypertension AT lizheng metaanalysisontheeffectandsafetyoflcz696inthetreatmentofhypertension AT binbinxia metaanalysisontheeffectandsafetyoflcz696inthetreatmentofhypertension AT xuqianzhang metaanalysisontheeffectandsafetyoflcz696inthetreatmentofhypertension AT yanzhao metaanalysisontheeffectandsafetyoflcz696inthetreatmentofhypertension |